View Older Stories View More Recent Stories

Aug 5, 2020 07:00AM EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Aug 4, 2020 07:00AM EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®
Jul 29, 2020 07:00AM EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
Jul 27, 2020 07:00AM EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting
Jul 13, 2020 07:00AM EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer
May 26, 2020 07:00AM EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 18, 2020 07:01AM EyePoint Pharmaceuticals (EYPT) Highlights Data Showcasing DEXYCU at ASCRS 2020 Virtual Meetings
May 18, 2020 07:00AM EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting
May 6, 2020 07:00AM EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Apr 29, 2020 08:00AM EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
Apr 1, 2020 11:35AM EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update
Mar 5, 2020 07:00AM EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress
Feb 27, 2020 07:00AM EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information
Feb 18, 2020 07:00AM EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®
Feb 3, 2020 05:27PM EyePoint Pharmaceuticals (EYPT) Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vei
Feb 3, 2020 05:24PM EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlu
Feb 3, 2020 05:24PM EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlu
Jan 27, 2020 07:11AM EyePoint Pharmaceuticals (EYPT), Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Ta
Jan 27, 2020 07:00AM EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiw
Jan 23, 2020 07:09AM EyePoint Pharmaceuticals (EYPT) Reports Prelim. Q4 & FY19 Revenue Results Above Consensus
Jan 23, 2020 07:00AM EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
Dec 4, 2019 07:06AM EyePoint Pharmaceuticals (EYPT) Announces Pact for Expanded Access of DEXYCU Within One of Largest Integrated Delivery Systems in U.S.
Dec 4, 2019 07:00AM EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.
Nov 19, 2019 10:54AM EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
Nov 14, 2019 07:00AM EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
Nov 7, 2019 06:00AM EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress
Nov 4, 2019 07:11AM EyePoint Pharmaceuticals (EYPT) Reports Addition of DEXYCU & YUTIQ to Department of Veteran Affairs Federal Supply Schedule
Nov 4, 2019 07:00AM EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
Nov 1, 2019 07:00AM EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®
Oct 24, 2019 07:00AM EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
Oct 2, 2019 04:15PM EyePoint Pharmaceuticals (EYPT) Reports Permanent & Specific J-Code for YUTIQ Now in Effect
Oct 2, 2019 04:05PM EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
Sep 27, 2019 07:00AM EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
Sep 26, 2019 07:00AM EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 9, 2019 07:00AM EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
Aug 7, 2019 06:00AM EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Jul 30, 2019 05:20PM EyePoint Pharmaceuticals (EYPT) Highlights Positive Data Showcasing YUTIQ at 2019 ASRS Meetings
Jul 30, 2019 04:15PM EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 25, 2019 07:18AM EyePoint Pharmaceuticals (EYPT) Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ by CMS
Jul 25, 2019 07:00AM EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)
Jul 24, 2019 07:00AM EyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information
Jul 23, 2019 07:00AM EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 15, 2019 07:05AM EyePoint Pharmaceuticals (EYPT) Names Wendy DiCicco, CPA, to Board
Jul 15, 2019 07:00AM EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
Jul 1, 2019 07:00AM EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
Jun 13, 2019 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 10, 2019 07:00AM EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires
May 15, 2019 07:00AM EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
May 8, 2019 06:00AM EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
May 1, 2019 07:27AM EyePoint Pharmaceuticals (EYPT) Highlights Positive YUTIQ 36-Month Follow-Up Phase 3 Data at 2019 ARVO Meetings
View More Recent Stories View Older Stories